摘要
目的通过对非小细胞肺癌（NSCLC）组织与癌旁组织中切除修复交叉互补基因1（ERCC1）、胸苷酸合成酶（Ts）的检测，探讨其表达与NSCLC临床特征及预后的关系，为NSCLC个体化治疗提供实验依据。方法采用免疫组化方法检测50例NSCLC患者术后癌组织和癌旁组织标本中ERCC1、TS蛋白的表达水平，探讨ERCC1、TS的表达与NSCLC患者总生存期（OS）、疾病进展时间（TTP）及中位OS、中位TTP之间的关系。结果（1）ERCC1、TS在NSCLC患者癌组织与癌旁组织中的阳性表达率比较，差异具有统计学意义（64．00％vs20．00％，X^2=19．87，P〈0．01；48．00％vs24．00％，x^2=6．25，P〈0．05）。（2）接受术后铂类方案化疗并随访，ERCC1阴性表达者中位0S明显长于阳性表达者（19．10个月vs10．00个月，x^2=8．133，P=0．002），中位TTP亦明显长于阳性表达者（15．30个月VS9．00个月，）（2=7．410，P=0．003）。TS阴性表达者的中位0s（17．80个月vs11．00个月，x^2=7．001，P=0．008）、中位TTP（11．40个月vs6．80个月，x^2=5．884，P=0．026）均明显长于TS阳性表达者。结论ERCC1、TS蛋白可能成为NSCLC患者对铂类药物敏感性的预测因子；二者联合检测有助于NSCLC患者个体化治疗方案的选择。
Objective To detect the excision repair cross-complementing gene 1 （ERCC1） and thymidylate of the acid synthase （TS） in non-small cell lung cancer （NSCLC） and its adjacent tissue, and investigate the relationship of the expression of ERCC1 and TS with the clinical characteristics of NSCLC and prognosis for NSCLC individual therapy to provide experimental basis. Methods The protein expression levels of ERCC1 and ＂IS in 50 cases of postoperative NSCLC cancer and adjacent tissue were detected by im- munohistochemieal method and the relationship among the expression of ERCC1, TS , and overall survival of patients with NSCLC Phase （ OS ） , disease progression time （ TFP ）, the median OS, and median TFP was analyzed. Results （1）There was an obvious difference between the expression of ERCC1, TS in cancer and paraneoplastic tissue of NSCLC ,which had statistically significance （64.00% vs 20. 00% ,X2 = 19.87, P 〈 0. 01 ;48.00% vs 24. 00%, X2 = 6. 25, P 〈 0. 05 ） ;（2）The continued investigation in the patients who received postoperative cisplatin or carboplatin chemotherapy showed that the 0S of negative expression of ERCC1 was significantly longer than the positive one （ 19. 10 vs 10.00 months ; ~2 = 8. 133, P = 0. 002）, so was median T＇FP （15.30 vs 9. 00 months; ~2 =7. 410, P =0. 003）. The median 0S of the negative expression of TS, was significantly longer than the positive one （ 17.80 vs 11.00 months, X^2 = 7.001, P = 0. 008）, so was median TTP （ 11.40 vs 6. 80 months;x^2 = 5. 884, P = 0. 026）. Conclusions ERCC1 and TS protein may become sensitive predictors of platinum chemosensitivity for NSCLC patients ; the detection of combined with ERCC1 and TS would contribute to the selection of individualized treatment programs for NSCLC.
出处
《中国医师杂志》
CAS
2013年第3期317-320,共4页
Journal of Chinese Physician
关键词
DNA结合蛋白质类
代谢
胸苷酸合酶
代谢
癌
非小细胞N
药物疗法
顺铂
治
疗应用
DNA-binding proteins/metabolism
Thymidylate synthase/metabolism
Carcinoma, non-small-cell lung/drug therapy
Cisplatin/therapeutic use
